GBA1 and depressive symptom measurement: Among the GBA carriers, some patients had distinctive clinical features, such as supranuclear vertical gaze palsy (P25), nonmedication associated hallucinations (P19), depression and anxiety (P13, P18), and early cognitive dysfunction in two patients (P13, P24).